Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009474 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Diwakar Davar und 19 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA davard@upmc.edu. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, CTLA-4 Antigen, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, Alpine Immune Sciences, Inc..
Abstract (Originalsprache)
Background
Davoceticept (ALPN-202) is an Fc fusion of a CD80 variant immunoglobulin domain designed to mediate programmed death-ligand 1 (PD-L1)-dependent CD28 co-stimulation while inhibiting the PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) checkpoints. The safety and efficacy of davoceticept monotherapy and davoceticept and pembrolizumab combination therapy in adult patients with advanced solid tumors were explored in NEON-1 and NEON-2, respectively.
Methods
In NEON-1 (n=58), davoceticept 0.001–10 mg/kg was administered intravenous either once weekly (Q1W) or once every 3 weeks (Q3W). In NEON-2 (n=29), davoceticept was administered intravenously at 2 dose levels (0.1 or 0.3 mg/kg) Q1W or Q3W with pembrolizumab (400 mg once every 6 weeks). In both studies, primary endpoints included incidence of dose-limiting toxicities (DLT); type, incidence, and severity of adverse events (AEs) and laboratory abnormalities; and seriousness of AEs. Secondary endpoints included antitumor efficacy assessed using RECIST v1.1, pharmacokinetics, anti-drug antibodies, and pharmacodynamic biomarkers.
Results
The incidence of treatment-related AEs (TRAEs) and immune-related adverse events (irAEs) was 67% (39/58) and 36% (21/58) with davoceticept monotherapy, and 62% (18/29) and 31% (9/29) with davoceticept and pembrolizumab combination, respectively. The incidence of ≥grade (Gr)3 TRAEs and ≥Gr3 irAEs was 12% (7/58) and 5% (3/58) with davoceticept monotherapy, and 24% (7/29) and 10% (3/29) with davoceticept and pembrolizumab combination, respectively. One DLT of Gr3 immune-related gastritis occurred during davoceticept monotherapy 3 mg/kg Q3W. During davoceticept combination with pembrolizumab, two Gr5 cardiac DLTs occurred; one instance each of cardiogenic shock (0.3 mg/kg Q3W, choroidal melanoma metastatic to the liver) and immune-mediated myocarditis (0.1 mg/kg Q3W, microsatellite stable metastatic colorectal adenocarcinoma), prompting early termination of both studies. Across both studies, five patients with renal cell carcinoma (RCC) exhibited evidence of clinical benefit (two partial response, three stable disease).
Conclusions
Davoceticept was generally well tolerated as monotherapy at intravenous doses up to 10 mg/kg. Evidence of clinical activity was observed with davoceticept monotherapy and davoceticept in combination with pembrolizumab, notably in RCC. However, two fatal cardiac events occurred with the combination of low-dose davoceticept and pembrolizumab. Future clinical investigation with davoceticept should not consider combination with programmed death-1-inhibitor anticancer mechanisms, until its safety profile is more fully elucidated. Trial registration number NEON-1 ( NCT04186637 ) and NEON-2 ( NCT04920383 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA davard@upmc.edu.
- University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Emory University Winship Cancer Institute, Atlanta, Georgia, USA.
- START Midwest, Grand Rapids, Michigan, USA.
- HonorHealth Research and Innovation Institute, Scottsdale, Arizona, USA.
- Linear Clinical Research, Nedlands, Western Australia, Australia.
ORCID-Profile: Diwakar Davar, Nehal Lakhani, Justin Moser, Rachel E Sanborn, Mario Sznol, Allison Naumovski
Förderung
- NCATS NIH HHS
- Alpine Immune Sciences, Inc.
Zitieren
APA
Davar, D., Cavalcante, L., Lakhani, N., Moser, J., Millward, M., McKean, M., Voskoboynik, M., Sanborn, R. E., Grewal, J. S., Narayan, A., Patnaik, A., Gainor, J. F., Sznol, M., Enstrom, A., Blanchfield, L., LeBlanc, H., Thomas, H., Chisamore, M. J., Peng, S. L., & Naumovski, A. (2024). Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009474
Vancouver
Davar D, Cavalcante L, Lakhani N, Moser J, Millward M, McKean M, et al. Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009474
BibTeX
@article{Davar2024,
author = {Davar, Diwakar and Cavalcante, Ludimila and Lakhani, Nehal and Moser, Justin and Millward, Michael and McKean, Meredith and Voskoboynik, Mark and Sanborn, Rachel E and Grewal, Jaspreet S and Narayan, Ajita and Patnaik, Amita and Gainor, Justin F and Sznol, Mario and Enstrom, Amanda and Blanchfield, Lori and LeBlanc, Heidi and Thomas, Heather and Chisamore, Michael J and Peng, Stanford L and Naumovski, Allison},
title = {Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009474}
}
EUVIMED